Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa
Executive Summary
Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa
You may also be interested in...
AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec
AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
FDA is understood to be considering the design of OSI/Genentech/Roche's Tarceva Phase III trial in refractory non-small cell lung cancer as a model for a postmarketing trial for AstraZeneca's Iressa